scispace - formally typeset
Journal ArticleDOI

The interferon signature in autoimmune diseases.

Lars Rönnblom, +1 more
- 01 Mar 2013 - 
- Vol. 25, Iss: 2, pp 248-253
Reads0
Chats0
TLDR
The observed IFN signature in several autoimmune diseases is a biomarker of active disease and is investigated as a tool when selecting treatment for individual patients.
Abstract
Purpose of reviewAn increased expression of type I interferon (IFN) regulated genes (an IFN signature) has been reported in blood and tissue cells from patients with SLE and other autoimmune diseases. We review the possible mechanisms behind the IFN signature as well as clinical and therapeutic cons

read more

Citations
More filters
Journal ArticleDOI

The role of activated monocyte IFN/SIGLEC1 signalling in Graves’ disease

TL;DR: In this paper , the role of monocytes in the pathology of Graves' disease was investigated and it was shown that type I IFN-induced sialic acid-binding immunoglobulin-like lectin1 (SIGLEC1) expression was significantly upregulated in untreated GD patients and correlated with thyroid parameters.
References
More filters
Journal ArticleDOI

Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus

TL;DR: Global gene expression profiling of peripheral blood mononuclear cells is used to identify distinct patterns of gene expression that distinguish most SLE patients from healthy controls, and identify a subgroup of patients who may benefit from therapies targeting the IFN pathway.
Journal ArticleDOI

Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood

TL;DR: Microarray analysis of blood cells reveals that immature granulocytes may be involved in SLE pathogenesis, and the IFN signature confirms the central role of this cytokine in Sle, using oligonucleotide microarrays.
Journal ArticleDOI

JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease

TL;DR: Not only have genome-wide association studies demonstrated that this pathway is highly relevant to human autoimmunity, but targeting JAKs is now a reality in immune-mediated disease.
Related Papers (5)